Serum protein binding of tolbutamide in patients treated with antiepileptic drugs. 1985

M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez

The possible development of a displacement interaction involving tolbutamide, in epileptic patients, has been explored by studying the serum protein binding of this drug in vitro in 199 samples of sera from patients treated with antiepileptic agents included in a programme of therapeutic drug monitoring. 82 of the samples were from patients receiving a single drug, 86 from patients treated with 2 drugs, and 31 from patients treated with 3 drugs. The free fraction of tolbutamide was higher in serum from patients treated with antiepileptic drugs than in serum from untreated 'normal' volunteers. The increase was more marked the greater the number of antiepileptic drugs administered. Valproate appeared to be the most powerful displacing agent.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002998 Clonazepam An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-,Klonopin,Antelepsin,Rivotril,Ro 5-4023,Ro 54023
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females

Related Publications

M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
March 1990, The Ceylon medical journal,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
November 1998, Pediatric neurology,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
November 1992, Epilepsy research,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
October 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
January 1980, Monographs in neural sciences,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
November 2010, The New England journal of medicine,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
November 2010, The New England journal of medicine,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
July 2012, Epilepsy & behavior : E&B,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
August 2010, The New England journal of medicine,
M C Fernández, and S Erill, and M I Lucena, and E Pita, and N Pérez-Alférez
January 1986, Therapeutic drug monitoring,
Copied contents to your clipboard!